To assess the inherent potential for detecting mild to moderate reductions in glomerular filtration rate, this study determined the biological variability of serum cystatin C and creatinine in 12 healthy subjects. After accounting for analytical variation, interindividual variance accounted for 93% and intraindividual variance accounted for 7% of serum creatinine biological variation. As such, to lie outside the assay reference interval, some subjects must exceed 13 SD from their usual mean value, whereas in others, a change of only 2 SD would be sufficient. For cystatin C, interindividual variation explained 25% and intraindividual variance explained 75% of biological variability. Therefore, the upper limit of the population reference interval for cystatin C is seldom more than 3-4 SD from the mean value of any healthy individual. The critical difference for sequential values significant at P <0.05 was calculated as 37% for serum cystatin C and 14% for serum creatinine. We conclude that cystatin C is potentially a better marker for detecting impaired renal function than serum creatinine, but serum creatinine is probably still the better marker for detecting temporal changes of renal function in individuals with established renal disease.
To assess the inherent potential for detecting mild to moderate reductions in glomerular filtration rate, this study determined the biological variability of serum cystatin C and creatinine in 12 healthy subjects. After accounting for analytical variation, interindividual variance accounted for 93% and intraindividual variance accounted for 7% of serum creatinine biological variation. As such, to lie outside the assay reference interval, some subjects must exceed 13 SD from their usual mean value, whereas in others, a change of only 2 SD would be sufficient. For cystatin C, interindividual variation explained 25% and intraindividual variance explained 75% of biological variability. Therefore, the upper limit of the population reference interval for cystatin C is seldom more than 3-4 SD from the mean value of any healthy individual. The critical difference for sequential values significant at P <0.05 was calculated as 37% for serum cystatin C and 14% for serum creatinine. We conclude that cystatin C is potentially a better marker for detecting impaired renal function than serum creatinine, but serum creatinine is probably still the better marker for detecting temporal changes of renal function in individuals with established renal disease.
Cystatin C is a low molecular weight protein that is produced by all nucleated cells and whose production rate is unaltered in inflammatory conditions. It is also filtered at the glomerulus and has therefore been proposed as a suitable marker for glomerular filtration rate (GFR) (1, 2) .
Cystatin C has been advocated as a better marker of GFR than serum creatinine because, unlike creatinine, it is not secreted by the renal tubule, is not affected by muscle mass, and does not suffer the same problems with analytical interference (3). These potential advantages have been reflected in several clinical studies, where measurement of cystatin C in patients with varying degrees of renal impairment has been shown to correlate more closely than serum creatinine to the Cr-labeled EDTA determination of GFR (3) (4) (5) . Despite this work, there has been no formal study investigating whether cystatin C could be used as a test for detecting renal impairment in subjects who are not already diagnosed as having kidney disease.
This study therefore aims to determine the potential of cystatin C, as compared with serum creatinine, as a screening test for impaired renal function by studying the biological variation of the analyte in healthy individuals.
There are now several methods for the measurement of cystatin C that are commercially available and easy to perform (6) but only one, the Dakopatts particle-enhanced turbidimetric assay, is available for use on routine nondedicated equipment. We chose this method, adapted for use on the Cobas Mira, Roche Products Ltd., to measure cystatin C concentrations in healthy laboratory workers and compared the results with a simultaneous study on the biological variation of serum creatinine in the same subjects.
Materials and Methods subjects
Twelve apparently healthy laboratory staff [seven men and five women; median age, 40 years (range 21-55 years)] participated in the study. Body mass index, fasting plasma glucose, current smoking status, and physical activity index (7) were recorded. Venous blood was collected into serum gel tubes (Becton Dickinson) on 10 2-week occasions at the same time each day (1400 -1500). Samples were separated by centrifugation at 2000g, and the serum was stored at Ϫ20°C within 1 h of collection.
The collection and analysis of samples complied with the ethical standards of South Manchester University Hospitals NHS Trust. reagents analyzer, using the manufacturer's recommended protocol. Serum creatinine was assayed using a kinetic Jaffe assay supplied by Bio-stat Ltd. The assay was again performed on a Cobas Mira S analyzer, using the manufacturer's recommended protocol.
Before analysis, all of the serum samples were thawed, thoroughly mixed, and then centrifuged at 10 000g to ensure clarity. The samples were analyzed in a single assay, randomized, and then reanalyzed in a second single assay. One analyst performed all the assays, and the same batches of reagent were used in both assays.
statistical analyses
Biovariability data was analyzed by calculating analytical, within-subject, and between-subject variances (SD A 2 , SD I 2 , and SD G 2 , respectively) according to the methods of Fraser and co-workers (8, 9) . By this technique, analytical variance (SD A 2 ) was calculated from the difference between duplicate results for each specimen (SD A 2 ϭ ⌺d 2 / 2N, where d is the difference between duplicates, and N is the number of paired results). The variance of the first set of results for each subject was used to calculate the average biological intraindividual variance (SD I 2 ) by subtraction of SD A 2 from the observed dispersion (equal to SD I 2 ϩ SD A 2 ). Subtracting SD I 2 ϩ SD A 2 from the overall variance of the set of first results determined the interindividual variance (SD G 2 ). We also calculated the index of individuality (SD I / SD G ), according to Harris and co-workers (8, 10) . When the index of individuality (IoI) for a particular test is Յ0.6, conventional population-based reference intervals are of limited value in the detection of unusual results for a particular individual. When the IoI is Ն1.4, the variation of a particular individual will fit those of the population's usual limits much more closely, allowing them to be used as intended.
After the IoI for each test was determined (8), the biological critical difference at the 5% significance level for both cystatin C and serum creatinine used the formula 2.77(mean CV I ). The critical difference for each test method (including analytical variation) was calculated by 2.77(CV I 2 ϩ CV A 2 ) 1/2 . Linear regression used the leastsquares method. Adherence to gaussian distributions was assessed using the Kolmogorov-Smirnov and Anderson Darling techniques. Subgroup comparisons were by unpaired t-tests. Table 1 gives details of the 12 individuals who participated in the study. Figure 1 shows the mean and range of cystatin C and serum creatinine values in the study subjects.
Results
The values for analytical, within-subject, and betweensubject CVs are shown in Table 2 . For cystatin C, the analytical variance contributed 24% of the total test variance, intraindividual variance contributed 57%, and interindividual variance contributed 19%. Thus, the IoI was 1.64. The index of heterogeneity was nonsignificant (0.95 SD from the theoretical CV (8)). The critical difference was 0.24 mg/L, i.e., 37% of the mean value in health.
For serum creatinine, the analytical variance contributed 3% of the total test variance, intraindividual variance contributed 7%, and interindividual variance contributed 91%. The IoI, therefore, was only 0.27. The index of heterogeneity was nonsignificant (0.39 SD from the theoretical CV). The critical difference was 12 mol/L, i.e., 14% of the mean value in health.
Serum creatinine concentrations were higher in men than women (95.9 Ϯ 13.2 mol/L vs 71.5 Ϯ 5.6 mol/L, P ϭ 0.002), but cystatin C concentrations showed no sex difference (0.658 Ϯ 0.05 mg/L for men vs 0.630 Ϯ 0.08 mg/L for women, P ϭ 0.49). Body mass index and subject age had no significant influence on creatinine or cystatin C concentrations(P Ͻ0.1). The mean values of serum creatinine and cystatin C in the study subjects were gaussian in distribution according to Kolmogorov-Smirnov and Anderson Darling statistics (both P Ͻ0.01). However, there was no linear correlation between mean cystatin C and mean serum creatinine values (r ϭ 0.18, P ϭ 0.58). Likewise, there was no linear relationship between the variance of cystatin C in a particular subject and the variance in that subject's serum creatinine, i.e., a subject with large fluctuations in one analyte during the study did not necessarily have large fluctuations in the other. Fig. 2a shows the distribution of serum creatinine values in two theoretical healthy subjects (A and B) who both have intraindividual variation identical to the mean biological value found in this study, i.e., SD ϭ 4.15 mol/L. The lower limit (Ϫ2 SD) of subject A's distribution coincides with the lower limit (Ϫ2 SD) of the biological reference range (53 mol/L), whereas the upper limit (ϩ2 SD) of subject B's distribution coincides with the upper limit of the biological reference range (118 mol/ L). This means that, in health, the serum creatinine of both subjects would usually lie within the reference interval. However, a movement of only 2 SD would render the mean creatinine value of subject B at the upper limit of the reference interval, whereas for subject A this would require a move of 13.7 SD from his or her usual mean value. Fig. 2b shows two additional theoretical subjects (C and D) who meet the same criteria as subjects A and B, but this time with the cystatin C assay being used. Again, a movement of 2 SD would render the mean cystatin C value of subject D at the upper limit of the reference interval. However, in comparison with subject A in the serum creatinine example, a move of only 3.4 SD for subject C would be required, using the cystatin C assay. 
Discussion
The accurate screening of subjects for impairment in renal function often requires either the laborious collection of timed urine samples or the intravenous injection of radioactive substances. Thus, the development of a simple serum test for detecting mild to moderate reductions in GFR would represent a major advance that would be of relevance to many fields of medicine. This study is consistent with previous ones in finding that the obvious candidate for such a test, serum creatinine, is limited by the high degree of between-individual variability found in healthy subjects (9) . This difference between subjects, or individuality, means that the population-based reference interval for creatinine is composed of subjects who each have their own narrow "reference range", and that each of these personal reference ranges differ substantially between individuals. As shown in Fig. 2a , this means that, to lie beyond the upper limit of the serum creatinine assay reference interval, some subjects with high creatinine values need only move a small amount (2 SD) outside their own personal reference ranges, whereas others, who usually have low creatinine values, must move Ͼ13 SD from their usual mean value. It thus seems pertinent to assume that a serum creatinine test will detect deteriorating GFR in the former subjects before it will in the latter, and may therefore explain why "normal" creatinine values are common in patients with mild to moderate renal impairment. This argument would not hold true if interindividual variations in GFR largely accounted for the differences in serum creatinine found between healthy subjects. However, other reports suggest that only 5% of the variance in serum creatinine between healthy individuals (inulin clearance Ͼ70 mL ⅐ min Ϫ1 ⅐ 1.73 m
Ϫ2
) can be explained on the basis of differences in GFR (11) . The remainder is presumably related to other factors that are independent of glomerular function, such as sex (as found with our data) and body composition differences between individuals. A possible way of circumventing this problem of serum creatinine having a low IoI (0.27 in this study) would be to stratify the sampled population into more homogeneous subgroups, for example, by sex or muscle mass (10) . However, it would be much more convenient to use a screening test for impaired renal function that did not have these numerous constraints.
Cystatin C would appear to be closer to fulfilling such a role. Fig. 1B shows that the spread of values found in each subject more closely approximates that of the group reference interval as a whole. As shown in Fig. 2b , this means that, in contrast to serum creatinine, the upper limit of the group reference interval for cystatin C is seldom more than 3-4 SD from the usual mean value of any healthy subject; therefore, rises above the reference range for an individual are more likely to be detected by a rise above the population reference interval. This is also reflected in the high IoI for the analyte (1.64), which, of relevance, is comparable with the findings of a previous study where creatinine clearance was used to assess GFR (9) .
If the relatively large intraindividual variation in cystatin C found in healthy subjects is an advantage in disease screening, then it may prove to be a disadvantage in the follow up of patients with established renal disease. This is because, for serum creatinine, a change in biological concentration of only 12 mol/L, i.e., equivalent to 14% of the mean value in health, is highly significant in the same individual-a figure that confirms previous work (9) . In contrast, two consecutive patient samples measuring cystatin C would have to differ by at least 37% of the reference mean value, i.e., 0.24 mg/L, to be regarded as significantly different, even if the instrument measuring them was perfectly precise. Again, this is a similar critical difference to that found for creatinine clearance and would indicate that, although cystatin C may be potentially better at detecting the onset of an abnormal GFR, it is perhaps not as sensitive as serum creatinine for detecting changes within the same individual.
Some of the possible limitations of this study warrant further discussion. For example, the accuracy of interindividual variations and group reference intervals for both serum creatinine and cystatin C could potentially be limited by the number of individuals participating in the study. However, the distribution of concentrations for both analytes was gaussian, and the study group's reference interval for serum creatinine (53-118 mol/L) is similar to values quoted from larger samples. In addition, the group's SD for cystatin C (0.12 mg/L) is consistent with the 0.1-0.15 mg/L values quoted using contemporary assay methods (3, 6) . Another aspect of the study requiring further consideration concerns the imprecision of the cystatin C method, which in our hands was higher than that of our chosen creatinine assay. However, one of the advantages of the type of study used here is that by eliminating the effect of analytical imprecision-and concentrating on biological variation-several aspects of the clinical utility of a diagnostic test can be assessed without hindrance from assay limitations.
In conclusion, because of its low individuality, cystatin C has fewer inherent limitations as a screening test for detecting deteriorating GFR than serum creatinine. However, serum creatinine is probably still the better assay for following sequential changes in an individual with confirmed renal disease.
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